SynthesisDiabetes, obesity & metabolism2025

Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials.

Huilin Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.